Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Falls Church, Virginia Clinical Trials

A listing of Falls Church, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (205) clinical trials

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Dose escalation of AB928 in combination with carboplatin/pemetrexed and AB928 in combination with carboplatin/pemetrexed plus pembrolizumab at standard doses will be assessed in participants with advanced metastatic non-squamous Non-Small Cell Lung Cancer. In this dose escalation combination study, participants will receive oral administration of AB928 as well as IV infused ...

Phase

5.27 miles

Learn More »

PF-06821497 Treatment Of Relapsed/Refractory SCLC Castration Resistant Prostate Cancer and Follicular Lymphoma

This is an open label, multi center, Phase 1 dose escalation study of PF 06821497 administered orally as a single agent BID to patients with SCLC, CRPC, DLBCL and FL (Part 1A). For Part 1B (dose escalation monotherapy), PF 06821497 will be administered as monotherapy in patients with FL. For ...

Phase

5.27 miles

Learn More »

A Study of LAM-003 in Patients With Acute Myeloid Leukemia

This clinical trial is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of LAM-003 across a range of LAM 003 dose levels when administered to subjects with previously treated relapsed or refractory AML. Subjects will self-administer oral LAM 003 either once or twice per day as ...

Phase

5.27 miles

Learn More »

MGD009/MGA012 Combination in Relapsed/Refractory Cancer

This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, PK, pharmacodynamics, immunogenicity, and preliminary antitumor activity of the combination of MGD009 and MGA012, each of which is administered by IV infusion.The study consists of a Dose Escalation Phase to determine ...

Phase

5.27 miles

Learn More »

First-in-human Study of DS-1062a for Advanced Solid Tumors

The dosage strength will change during the study but all participants will receive the same study drug. So the study is not a true 2-arm study, it is a 2-part study. In both parts, subjects with pathologically documented unresectable advanced NSCLC who have been refractory to or relapsed from standard ...

Phase

5.27 miles

Learn More »

Study of STRO-001 an Anti-CD74 Antibody Drug Conjugate in Patients With Advanced B-Cell Malignancies

This study is a first-in-human Phase 1, open-label, multicenter, dose escalation study with dose expansion to identify the maximum tolerated dose (MTD), the recommended phase 2 doses (RP2D) and to evaluate the safety, tolerability, and preliminary anti-tumor activity of STRO-001 in adult subjects with B-cell malignancies (MM and NHL) who ...

Phase

5.27 miles

Learn More »

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies

Dose escalation of the following will be assessed: escalating doses of AB928 in combination with pegylated liposomal doxorubicin (PLD) at standard doses in participants with advanced metastatic triple-negative breast cancer or ovarian cancer; escalating doses of IPI-549 in combination with the recommended phase 2 dose (RP2D) of AB928 and PLD ...

Phase

5.27 miles

Learn More »

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Dose escalation of AB928 in combination with mFOLFOX at standard doses will be assessed in participants with advanced metastatic GEC or CRC. In this dose escalation combination study participants will receive oral administration of AB928 as well as iv infusion of mFOLFOX. Dose expansion of AB928 in combination with mFOLFOX ...

Phase

5.27 miles

Learn More »

A Study of ASP1948 Targeting an Immune Modulatory Receptor in Subjects With Advanced Solid Tumors

This is a dose-escalation and expansion study of ASP1948 as a single agent and in combination with nivolumab. The study consists of 3 periods for monotherapy and combination therapy: screening, treatment and follow up, followed by an optional Re-treatment period for participants that qualify. The escalation cohorts will evaluate escalating ...

Phase

5.27 miles

Learn More »

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

This is a multi-center study of XMT-1536 in patients with tumors likely to express NaPi2b, focusing on patients with platinum-resistant ovarian cancer and non-small cell lung cancer, adenocarcinoma subtype. XMT-1536 will be administered as an intravenous infusion once every four weeks. The study consists of two segments: dose escalation (DES) ...

Phase

5.27 miles

Learn More »